TY  - JOUR
A1  - Blumenstein, Irina Ursula
A1  - Shanbhag, Satish
A1  - Langguth, Peter
A1  - Kalra, Philip A.
A1  - Zoller, Heinz
A1  - Lim, Wendy
T1  - Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety
T2  - Expert opinion on drug safety
N2  - Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM), and ferumoxytol (FER), are successful treatments for iron deficiency (Europe; FDI and FCM) and iron deficiency anemia (US; FDI, FCM, and FER). Areas covered: This review focusses on the chemistry and structure of FDI, FCM, and FER, and on three key aspects of IV iron safety: (1) hypersensitivity; (2) hypophosphatemia and sequelae; (3) cardiovascular safety. Expert opinion: Although the safety of modern IV iron has improved, immediate infusion reactions and the development of hypophosphatemia must be appreciated and recognized by those who prescribe and administer IV iron. Immediate infusion reactions can occur with any IV iron and are usually mild; severe reactions – particularly anaphylaxis – are extremely rare. The recognition and appropriate management of infusion reactions is an important consideration to the successful administration of IV iron. Severe, persistent, hypophosphatemia is a specific side effect of FCM. No cardiovascular safety signal has been identified for IV iron. Ongoing trials in heart failure will provide additional long-term efficacy and safety data.
KW  - Anemia
KW  - ferric carboxymaltose
KW  - ferric derisomaltose
KW  - ferumoxytol
KW  - heart failure
KW  - iron deficiency
KW  - iron isomaltoside
KW  - hypersensitivity
KW  - hypophosphatemia
KW  - intravenous iron
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62548
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-625487
SN  - 1744-764X
N1  - This work was supported by Pharmacosmos A/S, Holbæk, Denmark.
VL  - 20
IS  - 7
SP  - 757
EP  - 769
PB  - Routledge, Taylor & Francis
CY  - Abingdon, Oxon
ER  -